NJAAIS 2021 Annual Teaching Day

October 1, 2021

Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and New Jersey Allergy, Asthma, and Immunology Society (NJAAIS). The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s)TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists and allied healthcare providers in the field of allergy, asthma and immunology

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Be familiar with diagnosis and management of contact dermatitis.
  2. Recognize nasal polyps etiology and pathology as well as potential treatment approaches including biologics.
  3. Summarize immunodeficiency diagnosis and management, including genetic screening.
  4. Recognize different underlying etiologies and associated diseases in asthma, including fungal diseases.
  5. Follow current evidence-based research and guidelines in food allergy prevention and management.
  6. Realize the spectrum of different disorders in hypereosinophilia and to implement sound approaches in diagnosis and management.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

Ambulatory procedure centers

  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers


The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Course opens: 
Course expires: 
Event starts: 
10/01/2021 - 8:00am CDT
Event ends: 
10/01/2021 - 4:30pm CDT

David E Cohen, MD, MPH
Consultant and Honorarium:  Ferndale Laboratories, AsanaMedimetriks [past],Leo, UCB, Novartis, Dermavant, SFJ
FIDE. (FIDE receives industry sponsorship from AbbVie, Almirall, Amgen, Arcutis, Bausch and Lomb, Bristol-Myers Squibb, Celgene Dermavant, Dermira, Janssen, Kyowa Hakko Kirin, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, Regeneron, Sun Pharma, UCB, Valeant)

Brian Vickery, MD
Research Grant:  NIH-NIAID, Food Allergy Research and Education
Other research support:  Aimmune therapeutics, DBV technologies, Genentech, Regeneron, 
Consultant/advisory board:  Aimmune therapeutics, Aravax, AllerGenis, DBC, Food Allergy Research and Education, Reacta Biosciences

Maeve O’Connor, MD
Speaker: GlaskoSmithKline, Takeda, Teva, Astra Zeneca, Sanofi, Pharming, Circassia/Aerocine, Viropharma/Baxalta/Shire,  Regeneron, Optinose, GSK, Aimmune, Sanofi
Advisory Board: Strategic Pharmaceutical Strategic Allergy Advisors, Aimmune, Hycor, Precision, Pharming, Teva, ALK, Circassia, Spirometrix, Viropharma/Baxalta/Shire, Thermo Fisher Scientific

The following have no relevant financial relationships to disclose:
David Khan, MD
Joshua Milner, MD
Anne Maitland, MD, PHD

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Please login or create an account to take this course.